Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$41.18 USD

41.18
3,306,805

+0.86 (2.13%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is a Surprise in the Cards for Novartis in Q2 Earnings?

Swiss-giant Novartis (NVS) is all set to report second-quarter 2018 earnings on Jul 18. While the pharma business should maintain growth, the generic division is expected to be laggard.

    Pfizer (PFE) to Reorganize Business Into Three New Units

    Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.

      Merck's Keytruda Gets FDA's Priority Review for Liver Cancer

      The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.

        Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs

        Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.

          PFE vs. GSK: Which Stock Is the Better Value Option?

          PFE vs. GSK: Which Stock Is the Better Value Option?

            Novartis to Spin-Off Alcon as Separate Trading Company

            Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.

              New Strong Sell Stocks for July 2nd

              Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                Kinjel Shah headshot

                4 Drug and Biotech Stocks Awaiting FDA Decisions in July

                In the first six months of the year, the FDA grants approval to 17 new treatments.

                  Sanofi (SNY) Finalizes Deal for European Generic Unit Sale

                  Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.

                    Nitish Marwah headshot

                    Will a Trade War With China Wreak Havoc in US Healthcare?

                    It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.

                      Mylan, Lupin Collaborate for the Proposed Biosimilar Enbrel

                      Mylan (MYL) enters a partnership with Lupin Limited to commercialize a biosimilar of blockbuster drug Enbrel on approval.

                        Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA

                        Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.

                          Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection

                          Gilead's (GILD) HIV portfolio gets a further boost with the European Commission's approval of Biktarvy for HIV-1 infection.

                            Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

                            Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

                              Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

                              Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

                                Large Cap Pharma Stock Outlook: Short-Term Struggle Likely

                                Drug pricing scrutiny, pricing and competitive pressure, and major pipeline setbacks can hurt the performance of the large-cap pharmaceuticals sector in the short term.

                                  Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III

                                  Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen

                                    Company News For Jun 15, 2018

                                    Companies In The News are: ETSY,RCL,MYL,GSK,TWTR

                                      Mylan (MYL) to Get CRL Again for Generic Advair from FDA

                                      Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.

                                        Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication

                                        Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.

                                          The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works

                                          The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works

                                            Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer

                                            Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.

                                              Mark Vickery headshot

                                              Top Stock Reports for Chevron, Glaxo & T-Mobile

                                              Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Glaxo (GSK) and T-Mobile (TMUS).

                                                Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus

                                                Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.

                                                  Merck Presents Positive Melanoma Data on Keytruda at ASCO

                                                  Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda.